Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YAA OPPONG

Allopathic & Osteopathic Physicians Hospitalist

NPI
1487898748
CMS profile
405491
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$68.91

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $68.91 2

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $68.91 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YAA OPPONG

NPI 1487898748 · CMS profile ID 405491

Allopathic & Osteopathic Physicians / Hospitalist

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487898748?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YAA OPPONG, NPI 1487898748, CMS profile ID 405491. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487898748?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). YAA OPPONG, NPI 1487898748, CMS profile ID 405491. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487898748?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
YAA OPPONG, NPI 1487898748, CMS profile ID 405491, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1487898748?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $68.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $34.0711/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848313221 CMS
Merck Sharp & Dohme Corporation $34.8411/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848313223 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $393.80 19
PY2020 $120.65 7
PY2021 $68.91 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021
Generated from
OP_DTL_GNRL_PGYR2021_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $51,483.92 5
PY2022 Principal investigator $4,815,557.18 223
PY2021 Principal investigator $1,929,253.72 63

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

223 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $1,459.00 12/16/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229251
Principal investigator 1 Janssen Research & Development, LLC $12,915.00 11/21/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229245
Principal investigator 1 PFIZER INC. $6,390.00 11/16/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research LLC
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949759035
Principal investigator 1 Becton, Dickinson and Company $5,875.00 11/15/2022 Non-covered Recipient Entity
CAROLINA INSTITUTE FOR CLINICAL
SUST035 No dispute reported 06/30/2026 929560261
Principal investigator 1 Janssen Research & Development, LLC $3,298.00 11/07/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229243
Principal investigator 1 Janssen Research & Development, LLC $19,163.00 10/26/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229247
Principal investigator 1 Janssen Research & Development, LLC $200.00 10/19/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229249
Principal investigator 1 Cue Health Inc. $1,500.00 09/27/2022 Non-covered Recipient Entity
Wake Research
Clinical study for Flu No dispute reported 06/30/2026 924787597
Principal investigator 1 Janssen Research & Development, LLC $14,203.00 09/22/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 885229219
Principal investigator 1 Janssen Research & Development, LLC $2,075.00 09/22/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 885229221
Principal investigator 1 ModernaTX, Inc. $19,361.54 09/14/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963548383
Principal investigator 1 ModernaTX, Inc. $498.00 09/09/2022 Non-covered Recipient Entity
CAROLINA INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963291043
Principal investigator 1 Janssen Research & Development, LLC $17,980.00 08/26/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229227
Principal investigator 1 ModernaTX, Inc. $5,501.93 08/24/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548185
Principal investigator 1 ModernaTX, Inc. $9,775.22 08/24/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548279
Principal investigator 1 Janssen Research & Development, LLC $9,667.00 08/22/2022 Non-covered Recipient Entity
CAROLINA INSTITUTE FOR CLINICAL RES EARCH LLC
A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older No dispute reported 06/30/2026 885265471
Principal investigator 1 ModernaTX, Inc. $2,079.00 08/22/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548129
Principal investigator 1 ModernaTX, Inc. $17,894.25 08/22/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548303
Principal investigator 1 ModernaTX, Inc. $34,992.00 08/22/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548337
Principal investigator 1 Janssen Research & Development, LLC $12,051.00 08/19/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229225
Principal investigator 1 Janssen Research & Development, LLC $13,500.00 08/19/2022 Non-covered Recipient Entity
CAROLINA INSTITUTE FOR CLINICAL RES EARCH LLC
A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older No dispute reported 06/30/2026 885265469
Principal investigator 1 ModernaTX, Inc. $6,000.00 08/19/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963548379
Principal investigator 1 Merck Sharp & Dohme LLC $16,500.00 08/15/2022 Non-covered Recipient Entity
WR MCCR LLC
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age No dispute reported 06/30/2026 940395143
Principal investigator 1 ModernaTX, Inc. $970.99 08/15/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548065
Principal investigator 1 ModernaTX, Inc. $10,934.60 08/15/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548291
Principal investigator 1 ModernaTX, Inc. $18,057.60 08/15/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548305
Principal investigator 1 ModernaTX, Inc. $18,636.75 08/15/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548309
Principal investigator 1 ModernaTX, Inc. $35,268.75 08/15/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548341
Principal investigator 1 ModernaTX, Inc. $32,440.50 08/12/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548329
Principal investigator 1 ModernaTX, Inc. $2,600.00 08/12/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963548489
Principal investigator 1 ModernaTX, Inc. $155,273.00 08/12/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963548505
Principal investigator 1 ModernaTX, Inc. $19,505.94 08/10/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963548385
Principal investigator 1 Janssen Research & Development, LLC $21,935.00 08/08/2022 Non-covered Recipient Entity
CAROLINA INSTITUTE FOR CLINICAL RES EARCH LLC
A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older No dispute reported 06/30/2026 885265473
Principal investigator 1 ModernaTX, Inc. $4,540.05 08/05/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548173
Principal investigator 1 ModernaTX, Inc. $141.08 08/03/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963547841
Principal investigator 1 Janssen Research & Development, LLC $1,651.00 07/28/2022 Non-covered Recipient Entity
CAROLINA INSTITUTE FOR CLINICAL RES EARCH LLC
A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older No dispute reported 06/30/2026 885265467
Principal investigator 1 ModernaTX, Inc. $896.60 07/27/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548049
Principal investigator 1 ModernaTX, Inc. $970.99 07/27/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548063
Principal investigator 1 ModernaTX, Inc. $11,355.26 07/27/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548293
Principal investigator 1 Janssen Research & Development, LLC $60,143.00 07/22/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229223
Principal investigator 1 ModernaTX, Inc. $5,000.00 07/20/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548179
Principal investigator 1 ModernaTX, Inc. $9,709.86 07/20/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548277
Principal investigator 1 ModernaTX, Inc. $18,414.00 07/20/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548307
Principal investigator 1 ModernaTX, Inc. $1,941.97 07/15/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548127
Principal investigator 1 ModernaTX, Inc. $10,929.47 07/15/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548289
Principal investigator 1 ModernaTX, Inc. $37,507.05 07/15/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548349
Principal investigator 1 ModernaTX, Inc. $360.00 07/15/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963548485
Principal investigator 1 ModernaTX, Inc. $6,698.52 07/13/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963548381
Principal investigator 1 PFIZER INC. $981.50 07/13/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research LLC
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949758573
Principal investigator 1 ModernaTX, Inc. $1,028.57 07/01/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548373
Principal investigator 1 ModernaTX, Inc. $1,544.13 07/01/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548375
Principal investigator 1 PFIZER INC. $11,914.50 06/30/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research LLC
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949757937
Principal investigator 1 ModernaTX, Inc. $6,176.52 06/29/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548199
Principal investigator 1 ModernaTX, Inc. $7,930.98 06/29/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548231
Principal investigator 1 ModernaTX, Inc. $515.57 06/22/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548043
Principal investigator 1 ModernaTX, Inc. $1,523.61 06/22/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548099
Principal investigator 1 ModernaTX, Inc. $2,482.92 06/22/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548137
Principal investigator 1 ModernaTX, Inc. $3,883.94 06/22/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548163
Principal investigator 1 ModernaTX, Inc. $3,883.94 06/22/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548165
Principal investigator 1 ModernaTX, Inc. $4,027.05 06/22/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548171
Principal investigator 1 ModernaTX, Inc. $5,571.18 06/22/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548189
Principal investigator 1 Janssen Research & Development, LLC $43,595.00 06/17/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229201
Principal investigator 1 Janssen Research & Development, LLC $43,595.00 06/17/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229217
Principal investigator 1 ModernaTX, Inc. $970.99 06/15/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548059
Principal investigator 1 ModernaTX, Inc. $970.99 06/15/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548061
Principal investigator 1 ModernaTX, Inc. $1,941.97 06/15/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548125
Principal investigator 1 ModernaTX, Inc. $6,796.90 06/15/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548215
Principal investigator 1 ModernaTX, Inc. $18,785.25 06/15/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548311
Principal investigator 1 ModernaTX, Inc. $19,230.75 06/15/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548317
Principal investigator 1 ModernaTX, Inc. $7,062.19 06/10/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548219
Principal investigator 1 ModernaTX, Inc. $35,064.90 06/10/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548339
Principal investigator 1 ModernaTX, Inc. $35,648.10 06/10/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548343
Principal investigator 1 Janssen Research & Development, LLC $2,943.00 06/06/2022 Non-covered Recipient Entity
CAROLINA INSTITUTE FOR CLINICAL RES EARCH LLC
A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older No dispute reported 06/30/2026 885265465
Principal investigator 1 ModernaTX, Inc. $5,569.65 06/03/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963548377
Principal investigator 1 Janssen Research & Development, LLC $17,400.00 06/01/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229199
Principal investigator 1 Janssen Research & Development, LLC $17,400.00 06/01/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229215
Principal investigator 1 ModernaTX, Inc. $268.17 06/01/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548039
Principal investigator 1 ModernaTX, Inc. $970.99 06/01/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548057
Principal investigator 1 ModernaTX, Inc. $1,000.00 06/01/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548067
Principal investigator 1 ModernaTX, Inc. $5,473.71 06/01/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548183
Principal investigator 1 ModernaTX, Inc. $27,187.59 06/01/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548325
Principal investigator 1 ModernaTX, Inc. $38,839.42 06/01/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548355
Principal investigator 1 ModernaTX, Inc. $156,328.67 06/01/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548367
Principal investigator 1 Janssen Research & Development, LLC $48,481.00 05/30/2022 Non-covered Recipient Entity
CAROLINA INSTITUTE FOR CLINICAL RES EARCH LLC
A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older No dispute reported 06/30/2026 885265459
Principal investigator 1 Janssen Research & Development, LLC $1,057.00 05/27/2022 Non-covered Recipient Entity
CAROLINA INSTITUTE FOR CLINICAL RES EARCH LLC
A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older No dispute reported 06/30/2026 885265457
Principal investigator 1 Janssen Research & Development, LLC $1,234.00 05/27/2022 Non-covered Recipient Entity
CAROLINA INSTITUTE FOR CLINICAL RES EARCH LLC
A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older No dispute reported 06/30/2026 885265463
Principal investigator 1 Janssen Research & Development, LLC $48,594.00 05/20/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229197
Principal investigator 1 Janssen Research & Development, LLC $48,594.00 05/20/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229213
Principal investigator 1 Janssen Research & Development, LLC $1,746.00 05/17/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 885229205
Principal investigator 1 Janssen Research & Development, LLC $3,491.00 05/13/2022 Non-covered Recipient Entity
CAROLINA INSTITUTE FOR CLINICAL RES EARCH LLC
A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older No dispute reported 06/30/2026 885265455
Principal investigator 1 Janssen Research & Development, LLC $34,220.00 05/04/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229195
Principal investigator 1 Janssen Research & Development, LLC $34,220.00 05/04/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229211
Principal investigator 1 ModernaTX, Inc. $1,028.57 05/04/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548075
Principal investigator 1 ModernaTX, Inc. $1,028.57 05/04/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548077
Principal investigator 1 ModernaTX, Inc. $1,028.57 05/04/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548079
Principal investigator 1 ModernaTX, Inc. $1,241.46 05/04/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548095
Principal investigator 1 ModernaTX, Inc. $1,241.46 05/04/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548097
Principal investigator 1 ModernaTX, Inc. $3,742.34 05/04/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548157
Principal investigator 1 ModernaTX, Inc. $3,950.10 05/04/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548167
Principal investigator 1 ModernaTX, Inc. $6,386.85 05/04/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548211
Principal investigator 1 ModernaTX, Inc. $107,075.00 05/04/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963548503
Principal investigator 1 Janssen Research & Development, LLC $8,255.00 05/02/2022 Non-covered Recipient Entity
CAROLINA INSTITUTE FOR CLINICAL RES EARCH LLC
A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older No dispute reported 06/30/2026 885265461
Principal investigator 1 ModernaTX, Inc. $1,241.46 05/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548089
Principal investigator 1 ModernaTX, Inc. $1,241.46 05/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548091
Principal investigator 1 ModernaTX, Inc. $1,241.46 05/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548093
Principal investigator 1 ModernaTX, Inc. $2,482.92 05/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548131
Principal investigator 1 ModernaTX, Inc. $2,482.92 05/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548133
Principal investigator 1 ModernaTX, Inc. $2,482.92 05/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548135
Principal investigator 1 ModernaTX, Inc. $4,965.84 05/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548177
Principal investigator 1 ModernaTX, Inc. $6,207.30 05/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548203
Principal investigator 1 ModernaTX, Inc. $6,207.30 05/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548205
Principal investigator 1 ModernaTX, Inc. $6,207.30 05/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548207
Principal investigator 1 ModernaTX, Inc. $7,448.76 05/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548223
Principal investigator 1 ModernaTX, Inc. $7,448.76 05/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548225
Principal investigator 1 ModernaTX, Inc. $9,931.68 05/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548281
Principal investigator 1 ModernaTX, Inc. $9,931.68 05/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548283
Principal investigator 1 ModernaTX, Inc. $9,931.68 05/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548285
Principal investigator 1 ModernaTX, Inc. $11,568.15 05/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548295
Principal investigator 1 ModernaTX, Inc. $13,290.55 05/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548297
Principal investigator 1 ModernaTX, Inc. $17,824.19 05/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548301
Principal investigator 1 ModernaTX, Inc. $28,402.25 05/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548327
Principal investigator 1 ModernaTX, Inc. $37,446.30 05/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548347
Principal investigator 1 ModernaTX, Inc. $5,455.76 04/27/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548181
Principal investigator 1 Janssen Research & Development, LLC $37,588.00 04/22/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229193
Principal investigator 1 Janssen Research & Development, LLC $37,588.00 04/22/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229209
Principal investigator 1 ModernaTX, Inc. $202.50 04/22/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963547845
Principal investigator 1 ModernaTX, Inc. $1,028.57 04/22/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548073
Principal investigator 1 ModernaTX, Inc. $1,544.13 04/22/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548111
Principal investigator 1 ModernaTX, Inc. $1,843.09 04/22/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548117
Principal investigator 1 ModernaTX, Inc. $1,843.09 04/22/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548119
Principal investigator 1 ModernaTX, Inc. $5,660.96 04/22/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548195
Principal investigator 1 ModernaTX, Inc. $6,689.52 04/22/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548213
Principal investigator 1 ModernaTX, Inc. $13,684.28 04/22/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548299
Principal investigator 1 ModernaTX, Inc. $33,133.05 04/22/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548331
Principal investigator 1 ModernaTX, Inc. $1,028.57 04/20/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548071
Principal investigator 1 ModernaTX, Inc. $1,072.69 04/20/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548083
Principal investigator 1 ModernaTX, Inc. $1,544.13 04/20/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548109
Principal investigator 1 ModernaTX, Inc. $18,933.75 04/20/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548313
Principal investigator 1 Janssen Research & Development, LLC $4,969.00 04/12/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 885229203
Principal investigator 1 ModernaTX, Inc. $1,544.13 04/08/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548107
Principal investigator 1 ModernaTX, Inc. $2,572.70 04/08/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548139
Principal investigator 1 ModernaTX, Inc. $3,088.26 04/08/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548147
Principal investigator 1 ModernaTX, Inc. $3,088.26 04/08/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548149
Principal investigator 1 ModernaTX, Inc. $3,088.26 04/08/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548151
Principal investigator 1 ModernaTX, Inc. $5,660.96 04/08/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548193
Principal investigator 1 ModernaTX, Inc. $6,176.52 04/08/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548197
Principal investigator 1 ModernaTX, Inc. $6,207.30 04/08/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548201
Principal investigator 1 ModernaTX, Inc. $7,346.16 04/08/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548221
Principal investigator 1 ModernaTX, Inc. $2,456.25 04/08/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963548487
Principal investigator 1 Janssen Research & Development, LLC $109,620.00 04/06/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229191
Principal investigator 1 Janssen Research & Development, LLC $109,620.00 04/06/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229207
Principal investigator 1 ModernaTX, Inc. $268.17 03/30/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963547855
Principal investigator 1 ModernaTX, Inc. $268.17 03/30/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963547857
Principal investigator 1 ModernaTX, Inc. $268.17 03/30/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548035
Principal investigator 1 ModernaTX, Inc. $268.17 03/30/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548037
Principal investigator 1 ModernaTX, Inc. $970.99 03/30/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548053
Principal investigator 1 ModernaTX, Inc. $970.99 03/30/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548055
Principal investigator 1 ModernaTX, Inc. $1,843.09 03/30/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548115
Principal investigator 1 ModernaTX, Inc. $1,941.97 03/30/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548123
Principal investigator 1 ModernaTX, Inc. $3,958.50 03/30/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548169
Principal investigator 1 Janssen Research & Development, LLC $5,152.00 03/28/2022 Non-covered Recipient Entity
CAROLINA INSTITUTE FOR CLINICAL RES EARCH LLC
A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older No dispute reported 06/30/2026 885265453
Principal investigator 1 Janssen Research & Development, LLC $20,443.00 03/25/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229189
Principal investigator 1 Janssen Research & Development, LLC $20,443.00 03/25/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229241
Principal investigator 1 Janssen Research & Development, LLC $385,119.00 03/23/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229187
Principal investigator 1 Janssen Research & Development, LLC $385,119.00 03/23/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229239
Principal investigator 1 ModernaTX, Inc. $19,602.00 03/16/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548321
Principal investigator 1 ModernaTX, Inc. $38,600.55 03/16/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548353
Principal investigator 1 ModernaTX, Inc. $141.08 03/09/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963547839
Principal investigator 1 ModernaTX, Inc. $1,241.46 03/09/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548087
Principal investigator 1 ModernaTX, Inc. $1,544.13 03/09/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548105
Principal investigator 1 ModernaTX, Inc. $19,214.42 03/09/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548315
Principal investigator 1 ModernaTX, Inc. $12,800.00 03/09/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963548493
Principal investigator 1 Janssen Research & Development, LLC $3,766.00 03/08/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 885229253
Principal investigator 1 Janssen Research & Development, LLC $37,113.00 03/07/2022 Non-covered Recipient Entity
CAROLINA INSTITUTE FOR CLINICAL RES EARCH LLC
A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older No dispute reported 06/30/2026 885265447
Principal investigator 1 Janssen Research & Development, LLC $19,591.00 03/02/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229185
Principal investigator 1 Janssen Research & Development, LLC $19,591.00 03/02/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229237
Principal investigator 1 Janssen Research & Development, LLC $13,721.00 02/23/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229183
Principal investigator 1 Janssen Research & Development, LLC $13,721.00 02/23/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229235
Principal investigator 1 Janssen Research & Development, LLC $21,648.00 02/16/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229181
Principal investigator 1 Janssen Research & Development, LLC $21,648.00 02/16/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229233
Principal investigator 1 PFIZER INC. $56.62 02/14/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949758785
Principal investigator 1 ModernaTX, Inc. $141.08 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963547837
Principal investigator 1 ModernaTX, Inc. $268.17 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963547849
Principal investigator 1 ModernaTX, Inc. $268.17 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963547851
Principal investigator 1 ModernaTX, Inc. $268.17 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963547853
Principal investigator 1 ModernaTX, Inc. $536.34 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548045
Principal investigator 1 ModernaTX, Inc. $970.99 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548051
Principal investigator 1 ModernaTX, Inc. $1,028.57 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548069
Principal investigator 1 ModernaTX, Inc. $1,072.69 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548081
Principal investigator 1 ModernaTX, Inc. $1,544.13 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548101
Principal investigator 1 ModernaTX, Inc. $1,544.13 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548103
Principal investigator 1 ModernaTX, Inc. $1,609.03 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548113
Principal investigator 1 ModernaTX, Inc. $1,941.97 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548121
Principal investigator 1 ModernaTX, Inc. $2,627.84 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548141
Principal investigator 1 ModernaTX, Inc. $3,088.26 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548143
Principal investigator 1 ModernaTX, Inc. $3,088.26 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548145
Principal investigator 1 ModernaTX, Inc. $3,686.17 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548155
Principal investigator 1 ModernaTX, Inc. $3,754.41 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548159
Principal investigator 1 ModernaTX, Inc. $3,754.41 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548161
Principal investigator 1 ModernaTX, Inc. $5,529.26 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548187
Principal investigator 1 ModernaTX, Inc. $5,631.62 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548191
Principal investigator 1 ModernaTX, Inc. $6,801.10 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548217
Principal investigator 1 ModernaTX, Inc. $7,767.88 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548227
Principal investigator 1 ModernaTX, Inc. $7,767.88 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548229
Principal investigator 1 ModernaTX, Inc. $8,528.63 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548233
Principal investigator 1 ModernaTX, Inc. $9,709.86 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548275
Principal investigator 1 ModernaTX, Inc. $10,680.84 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548287
Principal investigator 1 ModernaTX, Inc. $19,602.00 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548319
Principal investigator 1 ModernaTX, Inc. $24,123.83 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548323
Principal investigator 1 ModernaTX, Inc. $36,450.00 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548345
Principal investigator 1 ModernaTX, Inc. $61,679.64 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548357
Principal investigator 1 ModernaTX, Inc. $65,970.39 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548359
Principal investigator 1 ModernaTX, Inc. $69,724.81 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548361
Principal investigator 1 ModernaTX, Inc. $154,215.29 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548365
Principal investigator 1 ModernaTX, Inc. $216,529.77 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548369
Principal investigator 1 ModernaTX, Inc. $514,220.85 02/02/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963548371
Principal investigator 1 Janssen Research & Development, LLC $32,794.00 01/28/2022 Non-covered Recipient Entity
CAROLINA INSTITUTE FOR CLINICAL RES EARCH LLC
A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older No dispute reported 06/30/2026 885265451
Principal investigator 1 Janssen Research & Development, LLC $44,180.00 01/26/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229179
Principal investigator 1 Janssen Research & Development, LLC $44,180.00 01/26/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229231
Principal investigator 1 Janssen Research & Development, LLC $29,746.00 01/21/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229177
Principal investigator 1 Janssen Research & Development, LLC $29,746.00 01/21/2022 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 885229229
Principal investigator 1 ModernaTX, Inc. $6,500.00 01/05/2022 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963548491
Principal investigator 1 Janssen Research & Development, LLC $65,106.00 01/03/2022 Non-covered Recipient Entity
CAROLINA INSTITUTE FOR CLINICAL RES EARCH LLC
A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older No dispute reported 06/30/2026 885265449